- Home
- YHGJ vs UBX Comparison
YHGJ vs UBX Comparison
Compare YHGJ & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- UBX
- Stock Information
- Founded
- YHGJ 1975
- UBX 2009
- Country
- YHGJ United States
- UBX United States
- Employees
- YHGJ N/A
- UBX N/A
- Industry
- YHGJ Specialty Chemicals
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- UBX Health Care
- Exchange
- YHGJ Nasdaq
- UBX Nasdaq
- Market Cap
- YHGJ 22.0M
- UBX 24.6M
- IPO Year
- YHGJ 1997
- UBX 2018
- Fundamental
- Price
- YHGJ $0.59
- UBX $1.00
- Analyst Decision
- YHGJ
- UBX Strong Buy
- Analyst Count
- YHGJ 0
- UBX 1
- Target Price
- YHGJ N/A
- UBX $8.00
- AVG Volume (30 Days)
- YHGJ 10.0K
- UBX 82.0K
- Earning Date
- YHGJ 11-08-2024
- UBX 11-04-2024
- Dividend Yield
- YHGJ N/A
- UBX N/A
- EPS Growth
- YHGJ N/A
- UBX N/A
- EPS
- YHGJ N/A
- UBX N/A
- Revenue
- YHGJ $18,559,000.00
- UBX N/A
- Revenue This Year
- YHGJ N/A
- UBX N/A
- Revenue Next Year
- YHGJ N/A
- UBX $33.62
- P/E Ratio
- YHGJ N/A
- UBX N/A
- Revenue Growth
- YHGJ 11.78
- UBX N/A
- 52 Week Low
- YHGJ $0.56
- UBX $1.00
- 52 Week High
- YHGJ $2.25
- UBX $2.02
- Technical
- Relative Strength Index (RSI)
- YHGJ 38.07
- UBX 28.85
- Support Level
- YHGJ $0.57
- UBX $1.10
- Resistance Level
- YHGJ $0.66
- UBX $1.23
- Average True Range (ATR)
- YHGJ 0.04
- UBX 0.06
- MACD
- YHGJ -0.00
- UBX -0.01
- Stochastic Oscillator
- YHGJ 18.18
- UBX 0.00
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.